[HTML][HTML] Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine …
E Atallah, MJ Mauro, A Hochhaus… - Journal of Cancer …, 2023 - Springer
Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
[HTML][HTML] Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine …
E Atallah, MJ Mauro, A Hochhaus… - Journal of Cancer …, 2023 - ncbi.nlm.nih.gov
Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
[PDF][PDF] Matching‑adjusted indirect comparison of asciminib versus other treatments in chronic‑phase chronic myeloid leukemia after failure of two prior tyrosine kinase …
E Atallah, MJ Mauro, A Hochhaus, C Boquimpani… - 2023 - academia.edu
Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase …
E Atallah, MJ Mauro, A Hochhaus… - Journal of Cancer …, 2023 - europepmc.org
Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase …
E Atallah, MJ Mauro, A Hochhaus… - Journal of Cancer …, 2023 - search.ebscohost.com
Purpose: The current standard of care for chronic-phase chronic myeloid leukemia (CP-
CML) is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP …
CML) is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP …
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase …
E Atallah, MJ Mauro, A Hochhaus… - Journal of cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
[引用][C] Matching‑adjusted indirect comparison of asciminib versus other treatments in chronic‑phase chronic myeloid leukemia after failure of two prior tyrosine kinase …
E Atallah, MJ Mauro, A Hochhaus… - Journal of Cancer …, 2023 - europepmc.org
Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …